Skin Cancer & Melanoma

Omid Hamid, MD, presented at the 22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies on the evolving landscape of perioperative immunotherapy and targeted therapy.

Researchers analyzed postoperative complications and survival outcomes in patients with melanoma who underwent therapeutic lymph node dissection.

Aminolevulinic acid plus red lamp therapy was given an sNDA by the FDA for the treatment of superficial basal cell carcinoma.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

IFx-2.0 showed a clinical benefit in an early phase 1 trial and has now been given orphan drug designation by the FDA for patients with stage IIB to IV cutaneous melanoma.

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

A phase 3 trial of iSCIB1+, a novel cancer vaccine, assessing patients with advanced melanoma has been cleared by the FDA.

Updated data from the 5-year analysis of KEYNOTE-942 of mRNA-4157/pembrolizumab in high-risk melanoma showed a maintained benefit.

Investigators are currently assessing treatment with Alpha DaRT among those with recurrent CSCC as part of the ReSTART trial.

Sorafenib improved the median progression-free survival compared with placebo among patients with metastatic uveal melanoma in the STREAM study.

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.

The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.